# Review Disposition: Cursor Comparison Validation

Date: 2026-05-26

## Scope

- Review source: `/speckit-analyze` findings discussed after implementation
- Feature: `docs/specs/034-cursor-comparison-validation/`
- Branch: `034-cursor-comparison-validation`

## Decision Gate

- Simpler/Faster: Resolve by narrowing evidence records and wording, not by
  changing Portolan runtime behavior.
- Blocking Edge Cases: Findings touch product-claim evidence and bounded
  artifact discipline, so stale ledger inputs would make the comparison
  overclaim.
- Existing Open Source: OSS producer execution remains `not_assessed`; this
  disposition does not substitute syft, jscpd, Semgrep, or relationship
  catalog outputs.

## Findings

| ID | Source | Decision | Evidence | Action |
| --- | --- | --- | --- | --- |
| I1 | speckit-analyze | accepted/fixed | `cursor-plus-portolan-output.md` records a strict rerun using only the context pack, `summary.json`, and `graph-index.json`; `comparison-ledger-2026-05-26.md` lane input artifacts now match that scope. | Re-ran the assisted lane under bounded first-pass inputs and removed stale `findings.jsonl` / `map.md` inputs from the ledger. |
| I2 | speckit-analyze | accepted/fixed | `spec.md` FR-005/FR-008 classify claims as accepted, narrowed, rejected, blocked, or inconclusive. | Updated the acceptance scenario and edge case wording so it no longer says only "failed or inconclusive". |
| U1 | speckit-analyze | accepted/fixed | PR review cycle artifacts are required before PR readiness closeout. | This disposition records the pre-PR analyze fixes; independent PR review lanes are run separately under `pr-review-*-2026-05-26.md`. |

## Verification

- `verified`: local file inspection confirmed ledger inputs and spec wording are
  aligned with the strict rerun and explicit claim enum.
- `failed`: none.
- `not_assessed`: PR state, GitHub checks, merge approval, UI Cursor/Composer,
  full ecosystem completeness, runtime topology, near-clone/SBOM duplication,
  and OSS producer execution.

## Remaining Risk

- The accepted product claim remains deliberately narrow: Portolan improved
  evidence discipline and bounded next-action quality on this headless local
  Bigtop comparison only.
